New Delhi, August 2015
Ahmedabad based Pharmaceuticals major, Torrent Pharmaceuticals Limited, today released its financial results for the Quarter ended 30th June, 2015.
Quarterly Financials
• For Q1 FY 2015-16 revenues were at Rs. 1,947 crores up by 75% from Rs. 1,114 crores during the same period last year. • EBITDA for Q1FY 2015-16 was at Rs.974 crores up by 156% from Rs. 380 crores during the same period last year. • PAT for Q1 2015-16 was at Rs. 449 crores up by 75% from Rs.256 crores during the same period last year. • The exceptional growth in the revenues and profits for the quarter is primarily on account of the launch of a new product in US market, which currently has limited competition. The continuation of this is dependent on competitive market conditions.
PERFORMANCE HIGHLIGHTS
BRANDED GENERICS
India Business
• Domestic formulation business recorded revenues of Rs. 491 crores for Q1 FY2015-16 growing by 39%.
• As per AIOCD, the domestic formulation business growth was 28% compared to covered market growth of 14% for Q1 FY 2015-16. (AIOCD Dataset June 2015)
GENERICS
USA
• Revenues from US operations for Q1 2015-16 registered growth of 231%.
